Figure 1 Rheumatoid arthritis development over time in relation to the level of inflammation Figure 1 | Rheumatoid arthritis development over time in relation.

Slides:

Advertisements

Similar presentations

Figure 1 Lymphocytes during the disease

Advertisements

Figure 6 Effects of adiponectin on podocyte function

Figure 3 Connexins in cartilage

Figure 1 Historical evolution of the clinical classification and

Figure 2 Representative MSI data obtained from human joints

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 3 Neuromuscular exercise

Figure 1 Enthesitis versus synovitis

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 2 Risk factors for sarcopenia

Figure 2 Heat map of targeted therapies in autoimmune diseases

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 2 Targeted versus untargeted metabolomics approaches

Figure 1 Metabolic profiling as a tool for studying rheumatic diseases

Figure 1 Schematic comparison of expected

Figure 3 Proportion of patients for whom NEDA

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 3 Simplified EULAR and GRAPPA

Figure 2 Simplified EULAR and GRAPPA

Figure 4 Antinuclear antibodies and disease activity in SLE

Figure 3 Transcriptome studies performed in the target

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Endocrinol. doi: /nrendo

Figure 2 Shared genetic loci in systemic autoimmune diseases

Figure 1 Location of HLA variants known to be associated

Figure 3 Strategies to achieve therapeutic inhibition of IL-1

Figure 4 Approaches to targeting inhibitory immune receptors

Figure 2 Cas9 targeting using crRNA (CRISPR

Figure 2 Overlap of associated loci among five rheumatic diseases

Figure 2 Interaction effects between heterozygous HLA‑DRB1

Nat. Rev. Rheumatol. doi: /nrrheum

Work arrangements, productivity, and self-confidence at work as affected by RA. a For example: Stopped working altogether, moved from full-time to part-time.

Figure 3 Statistical approaches for the analysis of metabolomic data

Figure 1 Cardiovascular risk and disease across the life-course

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 3 Multi-hit model for autoimmune diseases

Figure 1 Simplified EULAR and GRAPPA

Figure 1 Evolution of multiple sclerosis

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 2 Emerging hallmarks of T cells in rheumatoid arthritis

Nat. Rev. Urol. doi: /nrurol

Figure 1 Adaptive immune system of bacteria and archaea

Figure 1 Treat to target, remission and low disease activity in SLE

Figure 1 The current model of the pathogenesis of SLE

Figure 8 HRQOL in individuals with RA

Figure 6 Metabolism of pterins

Figure 1 Reproductive health in patients with rheumatic diseases

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 2 Phenotypes of osteoarthritis

The severity of fatigue over 8 years of disease in early rheumatoid arthritis patients. The severity of fatigue over 8 years of disease in early rheumatoid.

Figure 1 Patterns of joint and organ involvement in rheumatic disease

Different treatment strategies in rheumatoid arthritis in relation to radiographic progression (A) number of swollen joints (B) and fatigue severity over.

Figure 2 Clinical and histological features of the skin in dermatomyositis and conditions that mimic dermatomyositis Figure 2 | Clinical and histological.

Nat. Rev. Cardiol. doi: /nrcardio

Fatigue severity across early patients with arthritis with different diagnoses at disease onset (A) and over 3 years of disease (B). Fatigue severity across.

Nat. Rev. Rheumatol. doi: /nrrheum

EULAR-defined characteristics describing arthralgia at risk for RA

Figure 1 The role of macrophages in RA

The association between alcohol consumption and the severity of MRI-detected inflammation in hand and foot joints of (A) patients with RA and (B) asymptomatic.

Clinical expertise of GPs and rheumatologists in differentiating patients with arthralgia. Clinical expertise of GPs and rheumatologists in differentiating.

Satisfaction with control of RA

Schematic depiction of categories of inflammation in 350 small joints during progression from clinically suspect arthralgiato inflammatory arthritis. Schematic.

Patient-level radiographic progression of structural joint damage at year 1 and year 2 by original randomisation. Patient-level radiographic progression.

Presentation transcript:

Figure 1 Rheumatoid arthritis development over time in relation to the level of inflammation Figure 1 | Rheumatoid arthritis development over time in relation to the level of inflammation. Subclinical inflammation can progress to clinically detectable, persistent and classifiable rheumatoid arthritis (RA) (indicated by the blue line). The initiation of disease-modifying treatment in patients with arthralgia (that is, patients in the pre-arthritis phase who have symptoms such as joint point) might prevent disease development (indicated by the red line).The red dotted line indicates the clinical detection limit for measuring inflammation (thus, the transition from subclinical inflammation to clinically detectable inflammation) . This figure was adapted with permission obtained from van der Helm-van Mil, A. Nat. Rev. Rheumatol. 10, 171–180 (2014). UA, undifferentiated arthritis. This figure was adapted with permission obtained from van der Helm-van Mil, A. Nat. Rev. Rheumatol. 10, 171–180 (2014). UA, undifferentiated arthritis. van Steenbergen, H. W. et al. (2017) Preventing progression from arthralgia to arthritis: targeting the right patients Nat. Rev. Rheumatol. doi:10.1038/nrrheum.2017.185